S-1
Locally Advanced Rectal Cancer (LARC)
Tao ZhangPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
69 Active assets in the Locally Advanced Rectal Cancer (LARC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Sun Yat-sen University | Phase 4 | BBB |
FLUOROURACILUM Seoul National University Hospital | Phase 3 | BBB |
Eloxatin Sun Yat-sen University | Phase 3 | BBB |
Irinotecan Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | BB |
Capecitabine Tao Zhang | Phase 3 | BB |
View all 50 →
Same molecule, other indications
S-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →